PERKINELMER INC shareholders Q2 2022

PERKINELMER INC's ticker is PKI and the CUSIP is 714046109. A total of 578 filers reported holding PERKINELMER INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.2%.

PERKINELMER INC shareholders Q2 2022
Name	Shares	Value	Weighting ↓
Alpha DNA Investment Management LLC	9,009	$1,281,000	1.09%
TANDEM CAPITAL MANAGEMENT CORP /ADV	9,551	$1,358,000	1.09%
Wakefield Asset Management LLLP	15,778	$2,244,000	0.96%
ALTA CAPITAL MANAGEMENT LLC/	91,210	$12,971,000	0.95%
West Coast Financial LLC	37,643	$5,354,000	0.95%
DOWLING & YAHNKE LLC	136,386	$19,397,000	0.91%
Echo Street Capital Management LLC	690,938	$98,265,000	0.89%
Byrne Asset Management LLC	8,222	$1,169,000	0.86%
Impax Asset Management Group plc	1,234,379	$175,553,000	0.86%
Pflug Koory, LLC	10,104	$1,437,000	0.83%
Marks Group Wealth Management, Inc	40,181	$5,715,000	0.82%
Ativo Capital Management LLC	8,533	$1,213,000	0.82%
PARADIGM CAPITAL MANAGEMENT INC/NY	81,950	$11,655,000	0.79%
Rice Partnership, LLC	15,103	$2,148,000	0.75%
KING LUTHER CAPITAL MANAGEMENT CORP	913,385	$129,902,000	0.73%
Aspen Investment Management Inc	8,107	$1,153,000	0.72%
FIRST NATIONAL BANK OF OMAHA	83,045	$11,811,000	0.72%
Schrum Private Wealth Management LLC	4,000	$569,000	0.64%
Capital Research Global Investors	14,495,740	$2,061,585,000	0.64%
US Asset Management LLC	4,033	$574,000	0.63%

About PERKINELMER INC

PerkinElmer Inc. is a global leader in providing innovative solutions for the life sciences and diagnostics markets. The company's products and services are used by researchers, clinicians, and laboratories around the world to improve human health and advance scientific discovery.

PerkinElmer's portfolio includes a wide range of instruments, reagents, software, and services that enable customers to detect, analyze, and interpret complex biological and chemical information. The company's offerings span the entire drug discovery and development process, from target identification and validation to clinical trials and post-market surveillance.

One of PerkinElmer's key strengths is its expertise in imaging and detection technologies. The company's instruments are used to visualize and quantify biological processes at the cellular and molecular level, providing researchers with valuable insights into disease mechanisms and potential therapeutic targets.

PerkinElmer has also made significant investments in the field of diagnostics, with a focus on developing innovative solutions for early disease detection and personalized medicine. The company's offerings in this area include genetic testing, infectious disease screening, and cancer diagnostics.

Overall, PerkinElmer is well-positioned to benefit from the growing demand for advanced technologies in the life sciences and diagnostics markets. With a strong track record of innovation and a commitment to customer service, the company is poised for continued success in the years ahead.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists PERKINELMER INC's shareholders in Q2 2022. To view PERKINELMER INC's shareholder history, click here.